Loading…
Loading…
how should we think about the flow through of incrementals? You did not really touch on the incremental cost-out initiatives
There were mixed data points earlier this week from one of the companies that reported on China bioprocess
would love to just hear a little bit more about the strength on SCIEX and how much of that is the new product
talk about some of the puts and takes in the guide for the fourth quarter
for Beckman for next year, I mean, we can kind of get into a little bit more details when we give the formal numbers
you're not slowing through the entire EPS beat. I'm just curious, you know, if there are areas of maybe incremental caution
sounds like you're not flagging any incremental headwinds on volume-based procurement. You know, obviously, one of your periods did last week
We've seen, I think, $150 billion in new CapEx announced, including Roche today in the U.S. When do you think that becomes a tailwind
your comfort and your ability to take price, areas where you think you can push it more and maybe the mechanism to do it
anything you can say on kind of the long range outlook in '26, the Street's got you just under 7%
Is this mostly mass spec? Is it cryo EM? Any particular segments that are emerging
would love a little bit more color on the contract research side of the house
is there any reason that the CRO business isn't back to more normalized, call it, high single-digit growth
Can you maybe talk about the opportunity set there, how you feel about current capacity in fill-finish today
anything around order growth? Is this mostly share gains from your perspective? Much of this is bundling
trying to understand why now is the right time. Synergies for PPD have gone well. So any kind of bogey you can point to
I didn't actually hear what you're assuming for China growth this year. Assuming your products come off the trade restrictions list